Literature DB >> 9879811

Theophylline-induced mesenteric periarteritis in F344/N rats.

A Nyska1, R A Herbert, P C Chan, J K Haseman, J R Hailey.   

Abstract

The toxicity and carcinogenic potential of theophylline (an alkaloid bronchodilator drug) was investigated in male and female F344/N rats in 16-day, 14-week, and 2-year gavage and feeding studies. In 16-day studies, rats were fed diets containing 0, 500, 1000, 2000, 4000, and 8000 ppm of theophylline or given 0, 12.5 (twice daily), 25 (once daily), 50 (once daily), 50 (twice daily), 100 (once daily), 200 (once daily), 200 (twice daily), and 400 (once daily) mg theophylline/kg body weight in corn oil by gavage. In 14-week studies, rats were fed diets containing 0, 1000, 2000, and 4000 ppm theophylline or given 0, 37.5, 75, and 150 mg/kg body weight theophylline in corn oil by gavage. In 2-year gavage studies, rats were given 0, 7.5, 25, and 75 mg/kg body weight in corn oil. In 16-day gavage studies, treatment-related periarteritis occurred in arteries of the pancreas and adjacent to the mesenteric lymph nodes of early death male and female rats given 400 mg/kg once daily. In the 14-week studies, treatment-related periarteritis occurred at similar sites and in male rats exposed to 75 and 150 mg/kg, and in all exposed female rats (gavage studies), in females exposed to 1000 ppm, and in both sexes exposed to 2000 and 4000 ppm (feeding studies). In the 2-year study, chronic periarteritis was significantly increased only in the males receiving 75 mg/kg of theophylline. The adventitia, media and intima of medium- and large-sized mesenteric arteries were involved. Similar to other vasodilator chemicals, the pathogenesis of theophylline-induced vascular lesions may be a consequence of hemodynamic changes induced in the vascular wall.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9879811      PMCID: PMC7082802          DOI: 10.1007/s002040050567

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  6 in total

1.  Proceedings of the 2014 National Toxicology Program Satellite Symposium.

Authors:  Susan A Elmore; Michelle C Cora; Margarita M Gruebbel; Schantel A Hayes; Jessica S Hoane; Haruko Koizumi; Rachel Peters; Thomas J Rosol; Bhanu P Singh; Kathleen A Szabo
Journal:  Toxicol Pathol       Date:  2014-11-09       Impact factor: 1.902

Review 2.  An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease.

Authors:  Mark A Giembycz
Journal:  Br J Clin Pharmacol       Date:  2006-08       Impact factor: 4.335

Review 3.  Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease.

Authors:  Katharine H Banner; Neil J Press
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

4.  Successful drug development despite adverse preclinical findings part 2: examples.

Authors:  Robert A Ettlin; Junji Kuroda; Stephanie Plassmann; Makoto Hayashi; David E Prentice
Journal:  J Toxicol Pathol       Date:  2010-12-16       Impact factor: 1.628

5.  Theophylline is able to partially revert cachexia in tumour-bearing rats.

Authors:  Mireia Olivan; Jochen Springer; Sílvia Busquets; Anika Tschirner; Maite Figueras; Miriam Toledo; Cibely Fontes-Oliveira; Maria Inés Genovese; Paula Ventura da Silva; Angelica Sette; Francisco J López-Soriano; Stefan Anker; Josep M Argilés
Journal:  Nutr Metab (Lond)       Date:  2012-08-21       Impact factor: 4.169

6.  Increase in cardiovascular pathology in female Sprague-Dawley rats following chronic treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin and 3,3',4,4',5-pentachlorobiphenyl.

Authors:  Micheal P Jokinen; Nigel J Walker; Amy E Brix; Donald M Sells; Joseph K Haseman; Abraham Nyska
Journal:  Cardiovasc Toxicol       Date:  2003       Impact factor: 3.231

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.